The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...

Argentina Diabetes Devices Market To Reach US$ 1,031.89 Million By 2033, Growing At A CAGR Of 7.48% Astute Analytica ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

The global insulin delivery pen market is poised for remarkable growth, with its valuation projected to increase from USD ...

The global smart insulin pens market, currently estimated at US$ 3,927.3 million in 2023, is projected to exhibit robust ...

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...

The biggest talking point in the pharmaceutical industry at the moment revolves around treatments known as glucagon-like peptide-1 (GLP-1) agonists. GLP-1 agonists are used to treat diabetes and ...

Novo Nordisk should deliver a 24% CAGR over two years, driven by robust obesity drug market growth and improved operational performance, with an intrinsic value implying a 29% safety margin.

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NYSE ...

Novo Nordisk’s Phase 3 REDEFINE 1 study results for CagriSema have sparked a mixed reaction, with the drug achieving a 22.7% weight loss at 68 weeks, slightly edging out Lilly’s Zepbound at 22.5%.